Citations

Showing 10 of 108152 citations.

Mass Spectrometric Analysis of Urine from COVID-19 Patients for Detection of SARS-CoV-2 Viral Antigen and to Study Host Response
Mangalaparthi, Kiran K. , Singh, Smrita , Renuse, Santosh , Vanderboom, Patrick M. , Madugundu, Anil K. , Budhraja, Rohit , McAulay, Kathrine , Alexander, Mariam P., Badley, Andrew D. , Pandey, Akhilesh , Chavan, Sandip , Madugundu, Anil Kumar, Grys, Thomas E. , O'Horo, John C, Pandey, Akhilesh , Pandey, Akhilesh , Badley, Andrew D , Rule, Andrew D. , O’Horo, John C.

Mayo Clinic

Journal of Proteome Research | June 3, 2021 | Volume: 20 | Issue: 7 | Pages: 3404-3413

10.1021/acs.jproteome.1c00391 | PMID 34077217 Get It

Randomized Phase II Study of PET Response–Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial
Goodman, Karyn A. , Ou, Fang‐Shu , Bekaii‐Saab, Tanios , Fruth, Briant, Twohy, Erin , Meyers, Michael O. , Boffa, Daniel J., Mitchell, Kisha A. , Frankel, Wendy L. , Niedzwiecki, Donna , Thurmes, Paul J., Meyerhardt, Jeffrey A. , Ilson, David H. , Meyers, Michael O , Boffa, Daniel J , Mitchell, Kisha , Noonan, Anne , Janjigian, Yelena Y , O'Reilly, Eileen M , Meyerhardt, Jeffrey A , Ou, Fang-Shu , Niedzwiecki, Donna , Bekaii-Saab, Tanios S , Hall, Nathan C. , Noonan, Anne M. , Venook, Alan P. , O’Reilly, Eileen M.

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 25 | Pages: 2803-2815

10.1200/jco.20.03611 | PMID 34077237 Get It

PURPOSE To evaluate the use of early assessment of chemotherapy responsiveness by positron emission tomography (PET) imaging to tailor therapy in patients with esophageal and esophagogastric junction adenocarcinoma. METHODS After baseline PET, patients were randomly assigned to an induction chemotherapy regimen: modified oxaliplatin, leucovorin, and fluorouracil (FOLFOX) or carboplatin-paclitaxel (CP). Repeat PET was performed after induction; change in maximum standardized uptake value (SUV) from baseline was assessed. PET nonresponders (< 35% decrease in SUV) crossed over to the alternative chemotherapy during chemoradiation (50.4 Gy/28 fractions). PET responders (≥ 35% decrease in SUV) continued on the same chemotherapy during chemoradiation. Patients underwent surgery at 6 weeks postchemoradiation. Primary end point was pathologic complete response (pCR) rate in nonresponders after switching chemotherapy. RESULTS Two hundred forty-one eligible patients received Protocol treatment, of whom 225 had an evaluable repeat PET. The pCR rates for PET nonresponders after induction FOLFOX who crossed over to CP (n = 39) or after induction CP who changed to FOLFOX (n = 50) was 18.0% (95% CI, 7.5 to 33.5) and 20% (95% CI, 10 to 33.7), respectively. The pCR rate in responders who received induction FOLFOX was 40.3% (95% CI, 28.9 to 52.5) and 14.1% (95% CI, 6.6 to 25.0) in responders to CP. With a median follow-up of 5.2 years, median overall survival was 48.8 months (95% CI, 33.2 months to not estimable) for PET responders and 27.4 months (95% CI, 19.4 months to not estimable) for nonresponders. For induction FOLFOX patients who were PET responders, median survival was not reached. CONCLUSION Early response assessment using PET imaging as a biomarker to individualize therapy for patients with esophageal and esophagogastric junction adenocarcinoma was effective, improving pCR rates in PET nonresponders. PET responders to induction FOLFOX who continued on FOLFOX during chemoradiation achieved a promising 5-year overall survival of 53%.
COVID-19 and Global Oncology: A Year in Review
Desai, Aakash , Duma, Narjust , Lopes, Gilberto , Florez, Narjust , Desai, Aakash P

Mayo Clinic

JCO Global Oncology | June 2, 2021 | Volume: No volume available | Issue: 7 | Pages: 797-801

10.1200/go.21.00078 | PMID 34077258 Get It

BKMR-CMA: A Novel R Command for Mediation Analysis in Environmental Mixture Studies
Wang, A., Devick, Katrina L. , Bobbs, J.F., Coull, Brent A. , Navas‐Acién, Ana , Valeri, Linda

Mayo Clinic

ISEE Conference Abstracts | June 2, 2021 | Volume: 2020 | Issue: 1 | Pages: No page available

10.1289/isee.2020.virtual.p-0480 Get It

Use of Ultrasound to Assess Hemodynamics in Acutely Ill Patients
Safadi, Sami , Murthi, Sarah B. , Kashani, Kianoush , Murthi, Sarah , Kashani, Kianoush B

Mayo Clinic

Kidney360 | June 2, 2021 | Volume: 2 | Issue: 8 | Pages: 1349-1359

10.34067/kid.0002322021 | PMID 35369668 Get It

Abstract Early diagnosis of AKI and preventive measures can likely decrease the severity of the injury and improve patient outcomes. Current hemodynamic monitoring variables, including BP, heart and respiratory rates, temperature, and oxygenation status, have been used to identify patients at high risk for AKI. Despite the widespread use of such variables, their ability to accurately and timely detect patients who are high risk has been questioned. Therefore, there is a critical need to develop and validate tools that can measure new and more kidney-specific hemodynamic and laboratory variables, potentially assisting with AKI risk stratification, implementing appropriate and timely preventive measures, and hopefully improved outcomes. The new ultrasonography techniques provide novel insights into kidney hemodynamics and potential management and/or therapeutic targets. Contrast-enhanced ultrasonography; Doppler flow patterns of hepatic veins, portal vein, and intrakidney veins; and ultrasound elastography are among approaches that may provide such information, particularly related to vascular changes in AKI, venous volume excess or congestion, and fluid tolerance. This review summarizes the current state of these techniques and their relevance to kidney hemodynamic management.
Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY)
Boughey, Judy C. , Yu, Jia , Santo, Katelyn, Carter, Jodi M. , McLaughlin, Sarah A. , Moreno‐Aspitia, Alvaro , Northfelt, Donald W. , Gray, Richard J. , Hunt, Katie N. , Conners, Amy Lynn , Moyer, Ann M. , Weinshilboum, Richard, Copland, John A. , Wang, Liewei , Sinnwell, Jason P , Gray, Richard J , Ingle, J , Moyer, AM , Goetz, Matthew P , Boughey, JC , Carter, Jodi , Suman, Vera J. , Sinnwell, Jason P. , Kalari, Krishna R. , Tang, Xiaojia , Ingle, James N. , Goetz, Matthew P.

Mayo Clinic

Clinical Cancer Research | June 2, 2021 | Volume: 27 | Issue: 17 | Pages: 4696-4699

10.1158/1078-0432.ccr-21-0641 | PMID 34078650 Get It

Abstract Purpose: Patient-derived xenografts (PDX) are a research tool for studying cancer biology and drug response phenotypes. While engraftment rates are higher for tumors with more aggressive characteristics, it is uncertain whether engraftment is prognostic for cancer recurrence. Patients and Methods: In a prospective study of patients with breast cancer treated with neoadjuvant chemotherapy (NAC) with taxane ± trastuzumab followed by anthracycline-based chemotherapy, we report the association between breast cancer events and PDX engraftment using tumors derived from treatment naïve (pre-NAC biopsies from 113 patients) and treatment resistant (post-NAC at surgery from 34 patients). Gray test was used to assess whether the cumulative incidence of a breast cancer event differs with respect to either pre-NAC PDX engraftment or post-NAC PDX engraftment. Results: With a median follow-up of 5.7 years, the cumulative incidence of breast cancer relapse did not differ significantly according to pre-NAC PDX engraftment (5-year rate: 13.6% vs. 13.4%; P = 0.89). However, the incidence of a breast event was greater for patients with post-NAC PDX engraftment (5-year rate: 50.0% vs. 19.6%), but this did not achieve significance (P = 0.11). Conclusions: In treatment-naïve breast cancer receiving standard NAC, PDX engraftment was not prognostic for breast cancer recurrence. Further study is needed to establish whether PDX engraftment in the treatment-resistant setting is prognostic for cancer recurrence.
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Tolaney, Sara M. , Tayob, Nabihah , Dang, Chau T. , Isakoff, Steven J. , Valero, Vicente , Faggen, Meredith, Mulvey, Therese M. , Bose, Ron , Hu, Jiani , Weckstein, Douglas, Reeder‐Hayes, Katherine E. , Rugo, Hope S. , Ramaswamy, Bhuvaneswari , Zuckerman, Dan Sayam , Hart, Lowell L., Gadi, Vijayakrishna K. , Constantine, Michael, Cheng, Kit , Briccetti, Frederick , Schneider, Bryan P. , Garrett, Audrey Merrill, Marcom, Kelly, Albain, Kathy S. , DeFusco, Patricia, Ardman, Blair, Nanda, Rita , Jankowitz, Rachel C. , Rimawi, Mothaffar F. , Abramson, Vandana G. , Pohlmann, Paula R. , Poznak, Catherine Van , Forero‐Torres, Andres , Liu, Minetta C. , Ruddy, Kathryn J. , Rosenberg, Shoshana M. , Gelber, Richard D. , Trippa, Lorenzo , Barry, William T., DeMeo, Michelle K. , Burstein, Harold J. , Krop, Ian E. , Isakoff, Steven J , Mulvey, Therese Marie , Bose, Ron , Wolff, Antonio C , Reeder-Hayes, Katherine , Rugo, Hope S , Zuckerman, Dan , Gadi, Vijayakrishna K , Cheng, Kit , Briccetti, Frederick , Schneider, Bryan , Marcom, Paul Kelly , Albain, Kathy , Tung, Nadine , Nanda, Rita , Jankowitz, Rachel C , Rimawi, Mothaffar , Abramson, Vandana G , Van Poznak, Catherine , Forero-Torres, Andres , Liu, Minetta , Ruddy, Kathryn J , Zheng, Yue , Rosenberg, Shoshana , Trippa, Lorenzo , Partridge, Ann H , Winer, Eric , Krop, Ian E , Pohlmann, Paula , Yardley, Denise Aysel , Wolff, Antonio C. , Tung, Nadine , Zheng, Yue , Partridge, Ann H. , Winer, Eric P.

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 21 | Pages: 2375-2385

10.1200/jco.20.03398 | PMID 34077270 Get It

PURPOSE The ATEMPT trial was designed to determine if treatment with trastuzumab emtansine (T-DM1) caused less toxicity than paclitaxel plus trastuzumab (TH) and yielded clinically acceptable invasive disease-free survival (iDFS) among patients with stage I human epidermal growth factor receptor 2–positive (HER2+) breast cancer (BC). METHODS Patients with stage I centrally confirmed HER2+ BC were randomly assigned 3:1 to T-DM1 or TH and received T-DM1 3.6 mg/kg IV every 3 weeks for 17 cycles or T 80 mg/m 2 IV with H once every week × 12 weeks (4 mg/kg load →2 mg/kg), followed by H × 39 weeks (6 mg/kg once every 3 weeks). The co-primary objectives were to compare the incidence of clinically relevant toxicities (CRTs) in patients treated with T-DM1 versus TH and to evaluate iDFS in patients receiving T-DM1. RESULTS The analysis population includes all 497 patients who initiated protocol therapy (383 T-DM1 and 114 TH). CRTs were experienced by 46% of patients on T-DM1 and 47% of patients on TH ( P = .83). The 3-year iDFS for T-DM1 was 97.8% (95% CI, 96.3 to 99.3), which rejected the null hypothesis ( P < .0001). Serially collected patient-reported outcomes indicated that patients treated with T-DM1 had less neuropathy and alopecia and better work productivity compared with patients on TH. CONCLUSION Among patients with stage I HER2+ BC, one year of adjuvant T-DM1 was associated with excellent 3-year iDFS, but was not associated with fewer CRT compared with TH.
Revisiting the controversy: The role of fungi in chronic rhinosinusitis
Tyler, Matthew A. , Lam, Kent , Marino, Michael J. , Yao, William C. , Schmale, Isaac L. , Citardi, Martin J. , Luong, Amber , Luong, Amber U , Yao, William C , Tyler, Matthew A

Mayo Clinic

International Forum of Allergy & Rhinology | June 2, 2021 | Volume: 11 | Issue: 11 | Pages: 1577-1587

10.1002/alr.22826 | PMID 34076362 Get It

AbstractIn the last two decades, the development of culture‐independent genomic techniques has facilitated an increased appreciation of the microbiota‐immunity interactions and their role in a multitude of chronic inflammatory diseases such as chronic rhinosinusitis (CRS), asthma, inflammatory bowel disease and dermatitis. While the pathologic role of bacteria in chronic inflammatory diseases is generally accepted, the understanding of the role of fungi remains controversial. Chronic rhinosinusitis, specifically the phenotype linked to nasal polyps, represents a spectrum of chronic inflammatory diseases typically characterized by a type 2 immune response. Studies on the microbiota within sinus cavities from healthy and diseased patients have focused on the bacterial community, mainly highlighting the loss of diversity associated with sinus inflammation. Within the various CRS with nasal polyps (CRSwNP) phenotypes, allergic fungal rhinosinusitis presents an opportunity to investigate the role of fungi in chronic type 2 immune responses as well as the antifungal immune pathways designed to prevent invasive fungal diseases. In this review, we examine the spectrum of fungi‐associated sinus diseases highlighting the interaction between fungal species and host immune status on disease presentation. With a focus on fungi and type 2 immune response, we highlight the current knowledge and its limitations of the sinus mycobiota along with cellular interactions and activated molecular pathways linked to fungi.